A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Follicular Lymphoma

NCT ID: NCT06091254

Last Updated: 2025-10-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

462 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-12

Study Completion Date

2031-11-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL).

This study will be made up of two parts: Part 1 (non-randomized) and Part 2 (randomized - controlled).

The aim of Part 1 of the study is to see how safe and tolerable the study drug is when given alone.

The aim of Part 2 of the study is to see how the study drug works compared to rituximab (called the "comparator drug") and chemotherapy (the current standard of care for NHL). Standard of care means the usual medication expected and used when receiving treatment for a condition.

The study is looking at several other research questions, including:

* What side effects may happen from taking the study drug
* How much study drug is in the blood at different times
* Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
* How the study drug affects quality of life and ability to complete routine daily activities.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Follicular Lymphoma (FL)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Odronextamab

Part 1 is a safety run-in. All participants will receive odronextamab.

In part 2 participants will be randomly assigned in a 1:1 ratio to receive odronextamab followed by odronextamab maintenance.

Group Type EXPERIMENTAL

Odronextamab

Intervention Type DRUG

Administered by intravenous infusion (IV)

Rituximab + Investigator's Choice Chemotherapy

Part 2 only, participants will be randomized 1:1 to receive rituximab in combination with chemotherapy followed by rituximab maintenance.

Group Type ACTIVE_COMPARATOR

Rituximab

Intervention Type DRUG

Rituximab will be administered by IV, or subcutaneously (SC)

Cyclophosphamide

Intervention Type DRUG

Administered by IV as part of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) chemotherapy, or Cyclophosphamide, Vincristine, Prednisone (CVP) chemotherapy

Doxorubicin

Intervention Type DRUG

Administered by IV as part of CHOP chemotherapy

Vincristine

Intervention Type DRUG

Administered by IV as part of CHOP, and CVP chemotherapy

Prednisone/prednisolone

Intervention Type DRUG

Administered orally (PO) as part of CVP chemotherapy

Bendamustine

Intervention Type DRUG

Administered by IV as part of chemotherapy (Rituximab-Bendamustine)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Odronextamab

Administered by intravenous infusion (IV)

Intervention Type DRUG

Rituximab

Rituximab will be administered by IV, or subcutaneously (SC)

Intervention Type DRUG

Cyclophosphamide

Administered by IV as part of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) chemotherapy, or Cyclophosphamide, Vincristine, Prednisone (CVP) chemotherapy

Intervention Type DRUG

Doxorubicin

Administered by IV as part of CHOP chemotherapy

Intervention Type DRUG

Vincristine

Administered by IV as part of CHOP, and CVP chemotherapy

Intervention Type DRUG

Prednisone/prednisolone

Administered orally (PO) as part of CVP chemotherapy

Intervention Type DRUG

Bendamustine

Administered by IV as part of chemotherapy (Rituximab-Bendamustine)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

REGN1979 Rituxan Cytoxan Adriamycin Oncovin Deltasone/Omnipred Treanda

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis of Cluster of Differentiation 20\^+ (CD20\^+) FL Grade 1-3a, stage II bulky or stage III / IV
2. Need for treatment as described in the protocol
3. Have measurable disease on cross-sectional imaging documented by diagnostic imaging Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
5. Adequate bone marrow function and hepatic function, as described in the protocol

Exclusion Criteria

1. Central Nervous System (CNS) lymphoma or leptomeningeal lymphoma
2. Histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma
3. Waldenström Macroglobulinemia (WM, lymphoplasmacytic lymphoma), Grade 3b follicular lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma
4. Treatment with any systemic anti-lymphoma therapy
5. Infections and allergy/hypersensitivity to study drug or excipient, as described in the protocol
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Regeneron Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trial Management

Role: STUDY_DIRECTOR

Regeneron Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Arizona Cancer Center

Tucson, Arizona, United States

Site Status

David Geffen School of Medicine at UCLA

Los Angeles, California, United States

Site Status

UC Irvine Health

Orange, California, United States

Site Status

Investigative Clinical Research of Indiana

Noblesville, Indiana, United States

Site Status

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Site Status

Karmanos Cancer Institute

Detroit, Michigan, United States

Site Status

Hattiesburg Clinic

Hattiesburg, Mississippi, United States

Site Status

Icahn School of Medicine at Mt Sinai

New York, New York, United States

Site Status

Stony Brook University Hospital

Stony Brook, New York, United States

Site Status

Clinical Research Alliance Inc

Westbury, New York, United States

Site Status

University of North Carolina

Chapel Hill, North Carolina, United States

Site Status

Levine Cancer Institute

Charlotte, North Carolina, United States

Site Status

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

Center for Oncology and Blood Disorders

Houston, Texas, United States

Site Status

HOPE Cancer Center of East Texas

Tyler, Texas, United States

Site Status

Huntsman Cancer Institute - Oncology Division

Salt Lake City, Utah, United States

Site Status

University of Virginia

Charlottesville, Virginia, United States

Site Status

Virginia Commonwealth University

Richmond, Virginia, United States

Site Status

Prohealth Care Inc

Waukesha, Wisconsin, United States

Site Status

Ingham Institute

Liverpool, New South Wales, Australia

Site Status

Icon Cancer Centre - Wesley

Auchenflower, Queensland, Australia

Site Status

Flinders Medical Centre

Bedford Park, South Australia, Australia

Site Status

Monash Health

Clayton, Victoria, Australia

Site Status

Epworth Freemasons

East Melbourne, Victoria, Australia

Site Status

St Vincent's Hospital - Melbourne

Fitzroy, Victoria, Australia

Site Status

Alfred Hospital and Monash University

Melbourne, Victoria, Australia

Site Status

Ordensklinikum Linz

Linz, Osterreich, Austria

Site Status

Ordensklinikum Linz Gmbh, Elisabethinen

Linz, , Austria

Site Status

Uniklinikum Salzburg (LKH) Universitatsklinik fur Innere Medizin III

Salzburg, , Austria

Site Status

Medical University of Vienna

Vienna, , Austria

Site Status

Hanusch Krankenhaus

Vienna, , Austria

Site Status

AZ St.-Elisabeth Herentals vzw

Herentals, Antwerp, Belgium

Site Status

Hopital De Jolimont

Haine-Saint-Paul, Hainaut, Belgium

Site Status

Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital

Ghent, Oost-Vlaanderen, Belgium

Site Status

Ziekenhuis Netwerk Antwerpen Stuivenberg

Antwerp, , Belgium

Site Status

Institut Jules Bordet

Brussels, , Belgium

Site Status

Ensino e Terapia de Inovacao Clinica Amo (Etica)

Salvador, Estado de Bahia, Brazil

Site Status

Instituto Mario Pena de Ensino Pesquisa e Inovacao

Belo Horizonte, Minas Gerais, Brazil

Site Status

Liga Norte Riograndense Contra o Cancer

Natal, Rio Grande do Norte, Brazil

Site Status

Instituto do Cancer em Hospital Sao Vicente de Paulo

Passo Fundo, Rio Grande do Sul, Brazil

Site Status

Hospital de Clinicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Centro de Hematologia e Oncologia

Joinville, Santa Catarina, Brazil

Site Status

Animi Unidade de Tratamento Oncologico Ltda

Lages, Santa Catarina, Brazil

Site Status

Fundacao Pio XII Hospital de Amor

Barretos, São Paulo, Brazil

Site Status

Amaral Carvalho Hospital

Jaú, São Paulo, Brazil

Site Status

Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo

Ribeirão Preto, São Paulo, Brazil

Site Status

Instituto DOr de Pesquisa e Ensino Df Star

Brasília, , Brazil

Site Status

Instituto Nacional de Cancer Jose Alencar Gomes da Silva

Rio de Janeiro, , Brazil

Site Status

Instituto Americas

Rio de Janeiro, , Brazil

Site Status

Hospital Alemao Oswaldo Cruz

São Paulo, , Brazil

Site Status

AC Camargo Cancer Center

São Paulo, , Brazil

Site Status

Clinical Hospital of Medicine School at Sao Paulo University

São Paulo, , Brazil

Site Status

Casa de Saude Santa Marcelina

São Paulo, , Brazil

Site Status

Tom Baker Cancer Center

Calgary, Alberta, Canada

Site Status

Saint John Regional Hospital

Saint John, New Brunswick, Canada

Site Status

Cisss de la Monteregie-Centre

Greenfield Park, Quebec, Canada

Site Status

CHU de Quebec - Universite Laval

Québec, Quebec, Canada

Site Status

Ciusss de Lestrie - Centre Hospitalier Universitaire de Sherbrooke (CHUS)

Sherbrooke, Quebec, Canada

Site Status

Fundacion Arturo Lopez Perez

Santiago, Santiago Metropolitan, Chile

Site Status

Inmunocel

Santiago, Santiago Metropolitan, Chile

Site Status

Clinica Alemana de Santiago

Santiago, Santiago Metropolitan, Chile

Site Status

Centro Oncologia de Precision Universidad Mayor

Santiago, , Chile

Site Status

University Hospital Hradec Kralove

Hradec Králové, , Czechia

Site Status

University Hospital Kralovske Vinohrady

Prague, , Czechia

Site Status

Vseobecna Fakultni Nemocnice

Prague, , Czechia

Site Status

Centre Hospitalier Universitaire (CHU) Rennes

Rennes, Brittany Region, France

Site Status

Centre Hospitalier Regional Universitaire de Tours

Tours, Centre-Val de Loire, France

Site Status

Nantes University Hospital

Nantes, Pays de la Loire Region, France

Site Status

Hopital de la Conception

Marseille, Provence-Alpes-Côte d'Azur Region, France

Site Status

Centre Hospitalier Universitaire Angers

Angers, , France

Site Status

Institut Paoli Calmettes

Marseille, , France

Site Status

Hopital Saint Louis

Paris, , France

Site Status

Hopital Saint-Antoine

Paris, , France

Site Status

Centre Hospitalier Universitaire (CHU) de Poitiers

Poitiers, , France

Site Status

Institut de Cancerologie Strasbourg Europe (ICANS)

Strasbourg, , France

Site Status

Hopital Victor Dupouy Argenteuil

Argenteuil, Île-de-France Region, France

Site Status

Gustave Roussy

Villejuif, Île-de-France Region, France

Site Status

Robert-Bosch-Krankenhaus

Stuttgart, Baden-Wurttemberg, Germany

Site Status

University Hospital Wurzburg

Würzburg, Bavaria, Germany

Site Status

Kliniken Ostalb Stauferklinikum Schwab Gmund

Mutlangen, Gmund, Germany

Site Status

Clinic Frankfurt (Oder)

Frankfurt am Main, Hesse, Germany

Site Status

Universitatsmedizin der Johannes-Gutenberg Universitat Mainz

Mainz, Rhineland-Palatinate, Germany

Site Status

Hematological Praxis Dresden

Dresden, Saxony, Germany

Site Status

Charite Universitatsmedizin Berlin Campus Benjamin Franklin

Berlin, , Germany

Site Status

University Hospital Carl Gustav Carus

Dresden, , Germany

Site Status

Stadtisches Krankenhaus Kiel

Kiel, , Germany

Site Status

Samson Assuta Ashdod University Hospital

Ashdod, , Israel

Site Status

Bnai Zion Medical Center

Haifa, , Israel

Site Status

Hadassah Medical Center

Jerusalem, , Israel

Site Status

Galilee Medical Center

Nahariya, , Israel

Site Status

Rabin Medical Center

Petah Tikva, , Israel

Site Status

Chaim Sheba Medical Center

Ramat Gan, , Israel

Site Status

Tel Aviv Sourasky Medical Center

Tel Aviv, , Israel

Site Status

Istituto Romagnolo Per Lo Studio Dei Tumori

Meldola, Forli Cesena, Italy

Site Status

Irccs Aou Di Bologna- Policlinico Di Sant'Orsola Malpighi

Bologna, Italia, Italy

Site Status

Pia Fondazione Panico

Tricase, Lecce, Italy

Site Status

IRCCS Ospedale Policlinico San Martino

Genoa, Liguria, Italy

Site Status

Candiolo Cancer Institute, FPO, IRCCS

Candiolo, Torino, Italy

Site Status

UOC Ematologia e Terapia Cellulare - PO Mazzoni AST Ascoli Piceno

Ascoli Piceno, , Italy

Site Status

Azienda Ospedaliera Spedali Civili di Brescia

Brescia, , Italy

Site Status

Istituto Europeo di Oncologia

Milan, , Italy

Site Status

Federico II University

Napoli, , Italy

Site Status

AOU Maggiore della Carita-SCDU Ematologia

Novara, , Italy

Site Status

UO Ematologia Ravenna

Ravenna, , Italy

Site Status

Santa Maria della Misericordia

Udine, , Italy

Site Status

Ospedale dell'Angelo - Varese

Varese, , Italy

Site Status

Specjalistyczny Szpital im A. Sokolowskiego w Walbrzychu

Wałbrzych, Lower Silesian Voivodeship, Poland

Site Status

Uniwersytecki Szpital Kliniczny

Wroclaw, Lower Silesian Voivodeship, Poland

Site Status

Pratia MCM Krakow

Krakow, Malopolska, Poland

Site Status

Uniwersyteckie Centrum Kliniczne

Gdansk, Pomeranian Voivodeship, Poland

Site Status

Aidport

Skorzewo, Wielkopolska, Poland

Site Status

Cm Pratia Poznan

Skorzewo, Wielkopolska, Poland

Site Status

Pratia Onkologia Katowice

Katowice, , Poland

Site Status

Copernicus Memorial Hospital

Lodz, , Poland

Site Status

Centrum Innowacyjnych Terapii Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie

Lublin, , Poland

Site Status

Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Warszawa

Warsaw, , Poland

Site Status

Center for Hematologic Malignancy

Goyang-si, Gyeonggi-do, South Korea

Site Status

St. Vincents Hospital - The Catholic University of Korea

Suwon, Gyeonggi-do, South Korea

Site Status

Ajou University Hospital

Suwon, Gyeonggi-do, South Korea

Site Status

Dong-A University Hospital

Busan, , South Korea

Site Status

Pusan National University Hospital

Busan, , South Korea

Site Status

Jeonbuk National University Hospital

Jeonju, , South Korea

Site Status

Seoul St. Mary's Hospital

Seoul, , South Korea

Site Status

University Hospital of Santiago de Compostela

Santiago de Compostela, A Coruna, Spain

Site Status

Hospital Universitario Virgen De La Victoria Malaga

Málaga, Andalusia, Spain

Site Status

Hospital Universitario Virgen Macarena

Seville, Andalusia, Spain

Site Status

Son Espases University Hospital

Palma, Balearic Islands, Spain

Site Status

Cruces University Hospital (Hospital Universitario Cruces)

Barakaldo, Bizkaia, Spain

Site Status

Hospital Universitario Marques de Valdecilla

Santander, Cantabria, Spain

Site Status

Complejo Hospitalario Universitario de a Coruna

A Coruña, Galicia, Spain

Site Status

Hospital Universitario Quironsalud Madrid

Pozuelo de Alarcón, Madrid, Spain

Site Status

Hospital Clinico Universitario Virgen De La Arrixaca

El Palmar, Murcia, Spain

Site Status

Hospital Universitario de Navarra

Pamplona, Navarre, Spain

Site Status

Hospital Universitario Central De Asturias

Oviedo, Principality of Asturias, Spain

Site Status

University Hospital Vall d'Hebron

Barcelona, , Spain

Site Status

Hospital de la Santa Creu i Sant Pau

Barcelona, , Spain

Site Status

Hospital Virgen De Las Nieves De Granada

Granada, , Spain

Site Status

Gregorio Maranon

Madrid, , Spain

Site Status

Clinica Universidad de Navarra

Madrid, , Spain

Site Status

Fundacion Jimenez Diaz University Hospital

Madrid, , Spain

Site Status

University Hospital & Research Institute

Madrid, , Spain

Site Status

Hospital Universitario HM Sanchinarro, Servicio de Hematologia

Madrid, , Spain

Site Status

Morales Meseguer Hospital

Murcia, , Spain

Site Status

Complexo Hospitalario Universitario de Ourense

Ourense, , Spain

Site Status

Hospital Universitario de Salamanca

Salamanca, , Spain

Site Status

University Hospital Virgen del Rocio

Seville, , Spain

Site Status

Hospital Universitario Virgen de Valme

Seville, , Spain

Site Status

Hospital Clinico Universitario Valencia

Valencia, , Spain

Site Status

Hospital Universitari and Politecnic La Fe

Valencia, , Spain

Site Status

Hospital Clinico Lozano Blesa

Zaragoza, , Spain

Site Status

Kantonsspital Baden

Baden, Canton of Aargau, Switzerland

Site Status

Cantonal Hospital St Gallen

Sankt Gallen, Canton of St. Gallen, Switzerland

Site Status

Kantonsspital Winterthur Medical Oncology

Winterthur, Schweiz, Switzerland

Site Status

University Hospital Basel

Basel, , Switzerland

Site Status

Inselspital Bern University Hospital

Bern, , Switzerland

Site Status

Chang Gung Medical Foundation Chia Yi Branch

Buzi, Chiayi County, Taiwan

Site Status

Chang Gung Memorial Hospital Linkou

Taoyuan, Guishan District, Taiwan

Site Status

Changhua Christian Hospital

Changhua, , Taiwan

Site Status

Chung-Ho Memorial Hospital

Kaohsiung City, , Taiwan

Site Status

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, , Taiwan

Site Status

Taipei Medical University-Shuang Ho Hospital

New Taipei City, , Taiwan

Site Status

Taichung General Veterans Hospital

Taichung, , Taiwan

Site Status

National Cheng Kung University Hospital

Tainan City, , Taiwan

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

Taipei Veterans General Hospital

Taipei, , Taiwan

Site Status

Tri-Service General Hospital

Taipei, , Taiwan

Site Status

Taipei Municipal Wan Fang Hospital

Taipei, , Taiwan

Site Status

Ankara University Faculty of Medicine

Mamak, Ankara, Turkey (Türkiye)

Site Status

Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital

Yenimahalle, Ankara, Turkey (Türkiye)

Site Status

Gazi University

Ankara, Central Anatolia, Turkey (Türkiye)

Site Status

VM Medical Park Mersin Hospital

Mezitli, Mersin, Turkey (Türkiye)

Site Status

Tekirdag Namik Kemal University Hospital

Tekirdağ, Suleymanpasa, Turkey (Türkiye)

Site Status

Liv Hospital Ankara

Ankara, , Turkey (Türkiye)

Site Status

VKV American Hopital

Istanbul, , Turkey (Türkiye)

Site Status

Istanbul University Istanbul Faculty of Medicine

Istanbul, , Turkey (Türkiye)

Site Status

Ege University

Izmir, , Turkey (Türkiye)

Site Status

Erci̇yes Uni̇versi̇ty

Kayseri, , Turkey (Türkiye)

Site Status

Sakarya University Medical Faculty

Sakarya, , Turkey (Türkiye)

Site Status

Ondokuz Mayis Universitesi Tip Fakultesi Hastanesi

Samsun, , Turkey (Türkiye)

Site Status

Zonguldak Bulent Ecevit University

Zonguldak, , Turkey (Türkiye)

Site Status

Royal Cornwall Hospital NHS Trust

Truro, Cornwall, United Kingdom

Site Status

Derriford Hospital and the Royal Eye Infirmary

Plymouth, Devon, United Kingdom

Site Status

University Hospitals Dorset

Bournemouth, Dorset, United Kingdom

Site Status

Beatson West of Scotland Cancer Centre

Glasgow, Lanarkshire, United Kingdom

Site Status

Norfolk and Norwich University Hospital

Norwich, Norfolk, United Kingdom

Site Status

Barking, Havering and Redbridge University Hospitals NHS Trust

Romford, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Brazil Canada Chile Czechia France Germany Israel Italy Poland South Korea Spain Switzerland Taiwan Turkey (Türkiye) United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-502660-20-00

Identifier Type: CTIS

Identifier Source: secondary_id

R1979-HM-2298

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Odronextamab in Low Tumor Volume Advanced FL
NCT07128641 NOT_YET_RECRUITING PHASE2